A covalent inhibitor (THZ1) was developed that showed selectivity for CDK7, and specifically downregulated Myc in neuroblastoma (Chipumuro et al., 2014; Kwiatkowski et al., 2014). The gene discussed is MYC; the disease is neuroblastoma.